Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cystic Fibrosis Trials: CDER Officials Disagree Over Value Of FEV1 Endpoint

Executive Summary

There is an apparent split within FDA's Center for Drug Evaluation and Research on the usefulness of measuring the amount of air a patient can blow in one second as a primary outcome measure in trials of aerosolized antimicrobial drugs for cystic fibrosis.
Advertisement

Related Content

Novartis’ Tobramycin Inhalation Powder May Face Questions Over Study Endpoint
Cystic Fibrosis Trial Endpoints May Be Revised Following FDA Workshop
Gilead Prices Cystic Fibrosis Drug Cayston At Slight Premium To Competitor
Gilead Prices Cystic Fibrosis Drug Cayston At Slight Premium To Competitor

Topics

Advertisement
UsernamePublicRestriction

Register

PS052690

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel